- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07549321
hu14의 고위험 신경모세포종 환자에 대한 안전성 및 유효성 연구 (SHINE)
고위험 신경모세포종 환자에서 화학요법과 병용 투여된 hu14.18K322A 치료의 효능, 안전성 및 내약성을 특성화하고 평가하기 위한 2/3상 연구
Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.
연구 개요
상세 설명
This is a Phase 2/3, open label, single arm study, evaluating how well hu14.18K322A works and how safe it is in combination with chemotherapy, in relapsed and refractory high-risk neuroblastoma (HRNB) patients.
The study is in 2 parts. The first part of the study will test two doses of hu14.18K322A to give with chemotherapy in 12 patients to confirm the best dose. Once the best dose is found, Part 2 of the study will recruit up to an additional 66 participants with relapsed disease and 66 participants with refractory disease.
Children and young people who take part in the study must be between 18 months and 18 years old at the time of consent and have confirmed HRNB that has spread to other parts of the body. It is expected that participants will receive up to 12 cycles of treatment. Once the treatment has finished, participants will be followed up to study long-term effects.
연구 유형
등록 (추정된)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Copenhagen, 덴마크, 2100
- 모병
- Rigshospitalet
-
연락하다:
- Karsten Nysom, Dr
- 전화번호: 35 45 08 09
- 이메일: karsten.nysom@regionh.dk
-
-
-
-
-
Berlin, 독일, 13353
- 모병
- Charité - Universitätsmedizin Berlin
-
연락하다:
- Hedi Deubzer, Dr
- 전화번호: +49 30 450 566 715
- 이메일: hedwig.deubzer@charite.de
-
-
-
-
California
-
San Francisco, California, 미국, 94143
- 모병
- University of California San Francisco (UCSF)
-
연락하다:
- Kieuhoa Vo, Dr
- 전화번호: (415) 476-3831
- 이메일: Kieuhoa.Vo@ucsf.edu
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado Anschutz Medical
-
연락하다:
- Navin Pinto MD, MD
- 전화번호: 720-777-8134
- 이메일: navin.pinto@childrenscolorado.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- The University of Chicago
-
연락하다:
- Ami V Desai, Dr
- 전화번호: 773-702-6808
- 이메일: adesai12@bsd.uchicago.edu
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55454
- 모병
- University of Minnesota Masonic Children's Hospital
-
연락하다:
- Robin Williams, MD
- 전화번호: 612-626-2778
- 이메일: will4877@umn.edu
-
-
New York
-
The Bronx, New York, 미국, 10467
- 모병
- The Children's Hospital at Montefiore
-
연락하다:
- Alice Lee, MD
- 전화번호: 718-741-2342
- 이메일: alee5@montefiore.org
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- 모병
- Duke University Medical Center
-
연락하다:
- Jessica Sun, MD
- 전화번호: 919-684-3401
- 이메일: jessica.sun@duke.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
연락하다:
- Rochelle Bagatell MD
- 전화번호: +1 (215) 590-2299
- 이메일: bagatellr@chop.edu
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern
-
연락하다:
- Tanya C Watt
- 전화번호: 6147955338
- 이메일: Tanya.Watt@utsouthwestern.edu
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- University Hospital Vall d'Hebron
-
연락하다:
- Lucas Moreno Retortillo, Dr
- 전화번호: 2887 934 89 30 00
- 이메일: lucas.moreno@vallhebron.cat
-
Barcelona, 스페인, 08950
- 모병
- Hospital Sant Joan de Deu
-
연락하다:
- Jaume Mora, Dr
- 전화번호: +34 93 600 97 33
- 이메일: jaume.mora@sjd.es
-
Madrid, 스페인, 28009
- 모병
- Hospital Infantil Universitario Niño Jesús
-
연락하다:
- Beatriz Vergara Munoz, Dr
- 전화번호: +34616531224
- 이메일: beatriz.vergara@salud.madrid.org
-
-
-
-
-
Newcastle upon Tyne, 영국, NE1 4LP
- 모병
- Royal Victoria Infirmary
-
연락하다:
- Quentin Campbell-Hewson, Dr
- 전화번호: 0191 2821337
- 이메일: quentin.campbellhewson@nhs.net
-
Sutton, 영국, SM2 5PT
- 모병
- Royal Marsden NHS Foundation Trust
-
연락하다:
- Sucheta J Vaidya, Dr
- 전화번호: 023 8120 6334
- 이메일: sucheta.vaidya@icr.ac.uk
-
-
Hampshire
-
Southampton, Hampshire, 영국, SO16 6YD
- 모병
- Southampton Children's Hospital
-
연락하다:
- Juliet Gray, Dr
- 전화번호: +44-(0)23 8120 5213
- 이메일: juliet.gray@uhs.nhs.uk
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1E8
- 모병
- The Hospital for Sick Children
-
연락하다:
- Daniel Morgenstern, DR
- 전화번호: 427565 416-813-7654
- 이메일: daniel.morgenstern@sickkids.ca
-
-
-
-
-
Marseille, 프랑스, 13005
- 모병
- La Timone Children's Hospital
-
연락하다:
- Gabriel Revon-Riviere, Dr
- 전화번호: 04 91 38 68 22
- 이메일: gabriel.revon-riviere@ap-hm.fr
-
Paris, 프랑스, 75005
- 모병
- Institut Curie
-
연락하다:
- Amaury Leruste, Dr
- 전화번호: +33 (0)1 44 32 40 15
- 이메일: amaury.leruste@curie.fr
-
Villejuif, 프랑스, 94800
- 모병
- Gustave Roussy
-
연락하다:
- Pablo Berlanga, Dr
- 전화번호: (+33) 142 11 41 67
- 이메일: PABLO.BERLANGA@gustaveroussy.fr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
-
Are ≥18 months to <18 years of age at time of informed consent or assent.
-
Are initially diagnosed with histologically proven HRNB with metastatic disease.
-
Have evaluable or measurable disease per International Neuroblastoma Response Criteria (INRC)
-
Have a Lansky performance status of ≥50 (≤16 years ) or Karnofsky performance status ≥50% (for >16 years).
-
Have recovered from the toxic effects of prior chemotherapies
-
Are at least 2 weeks beyond any major tumor surgery
-
Meet the following organ function criteria, as measured within 1 week prior to Investigational Medicinal Product (IMP) dosing:
- BM function: i. Platelets ≥50 × 109/L ii. Absolute neutrophil count (ANC) ≥0.50 × 109/L
- Renal function: i. Age-adjusted serum creatinine ≤1.5 × upper limit of normal (ULN) for age. ii. Estimated glomerular filtration rate (eGFR) at least 60 mL/min using the Schwartz formula.
- Liver function: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3 × ULN and total bilirubin ≤1.5 × ULN.
- Cardiac function: i. Shortening fraction ≥27% or ejection fraction of ≥50% on echocardiogram. ii. Corrected QT Interval on electrocardiogram (ECG) using the Fridericia formula (QTcF) ≤ 480 msec.
- Lung function: i. Pulse oximetry considered normal in room air. No evidence of dyspnea at rest.
- Central nervous system (CNS) function: i. Participants with a history of CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.
-
If a fertile and sexually active woman of child-bearing potential (WOCBP), have a negative serum pregnancy test at Screening and then either a negative serum or urine test prior to each cycle and agree to use an acceptable and highly effective contraception method during the study and for at least 6 months after the last day of study treatment .
-
If a fertile and sexually active male, agree to use condoms during the study and for at least 6 months after the last dose of study treatment
-
If applicable based on age, are willing and able to provide voluntary written informed assent for participation in the study (as per local Institutional Review Board [IRB]/Independent Ethics Committee [IEC] requirements and if applicable based on regional age of consent) and to comply with all protocol requirements.
-
Their parent or legal guardian (if applicable based on regional age of consent) is willing and able to provide voluntary written informed consent for the participant's involvement in the study.
Exclusion Criteria
-
Any active uncontrolled infection at the time of enrollment. Any known history of infection with human immunodeficiency virus (HIV), or active or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Any contraindications to any of the study treatments.
-
Patients with >Grade 2 diarrhea.
-
Patients with disease of any major organ system that would compromise their ability to withstand chemoimmunotherapy.
-
Patients who have undergone a prior allogeneic stem cell transplant < 6 months ago or have undergone a solid organ transplant.
-
Patients who are on hemodialysis.
-
Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study except to manage allergic reactions
-
Patients on any other immunosuppressive medications
-
Patients who have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, or carbamazepine for at least 7 days prior to study enrollment.
-
Patients who have been diagnosed with any malignancy other than neuroblastoma.
-
Patients with symptoms of congestive heart failure.
-
Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required permanent discontinuation of the anti-GD2 therapy.
-
Patients participating in or planning to participate in another study that is either blinded or involves an IMP
-
If female, are breastfeeding, pregnant, or planning to become pregnant, or, if sexually active and of child-bearing potential, are unwilling to use an effective birth control method until 6 months after the last dose of study medication
-
Do not meet the following required washout periods prior to the administration of the first dose of hu14.18K322A:
- 14 days from prior systemic myelosuppressive chemotherapy.
- 7 days from prior systemic biologic antineoplastic agents (e.g. anti-cancer agents not known to be myelosuppressive - not associated with reduced platelet or ANC counts).
- 14 days from systemic steroids.
- ≥12 weeks from large field radiation therapy (i.e., total body irradiation, whole abdominal, total lung, ≥50% pelvis).
- 6 weeks from prior craniospinal radiotherapy or Iodine-131-metaiodobenzylguanidine (131I-MIBG) therapy.
- 2 weeks from radiotherapy to the primary tumor bed.
- ≥7 days from small treatment field radiation.
- 14 days or 5 half-lives (whichever is longer) from last administration of an IMP.
- >7 days prior to study enrollment for drugs that are strong inducers or inhibitors of Cytochrome P450 3A4 (CYP3A4).
- ≥21 days and with recovery of all associated toxicities from receiving cellular therapy (e.g., modified T lymphocyte cells, Natural Killer (NK) cells, dendritic cells).
-
Ongoing need for any medication known or suspected to interfere with study treatment.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: 더 높은 용량
|
21-day cycle for a maximum of 12 cycles |
|
다른: 낮은 용량
|
21-day cycle for a maximum of 12 cycles |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate (ORR)
기간: Assessed at end of treatment (up to 12 months)
|
Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve a complete response (CR) or partial response (PR) according to the International Neuroblastoma Response Criteria (INRC) |
Assessed at end of treatment (up to 12 months)
|
|
Metastatic complete response rate (mCRR)
기간: Assessed at end of treatment (up to 12 months)
|
Proportion of participants treated with hu14.18K322A in combination with chemotherapy who achieve an overall metastatic complete response (mCR) response |
Assessed at end of treatment (up to 12 months)
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
전체 생존(OS)
기간: 최대 3년
|
최대 3년
|
|
전체 전이 반응률(mORR)
기간: 치료 종료 시 (최대 12개월) 평가
|
치료 종료 시 (최대 12개월) 평가
|
|
반응 지속 기간 (DOR)
기간: 첫 반응 시점부터 질병 진행, 연구 중단, 새로운 치료 시작 또는 사망 시점까지
|
첫 반응 시점부터 질병 진행, 연구 중단, 새로운 치료 시작 또는 사망 시점까지
|
|
무진행 생존 기간 (PFS)
기간: 주기 1 시작부터 진행이 처음 발생할 때까지 최대 3년 동안 추적
|
주기 1 시작부터 진행이 처음 발생할 때까지 최대 3년 동안 추적
|
|
무사건 생존율 (EFS)
기간: 주기 1의 시작부터 진행, 이차성 악성 종양 또는 모든 원인으로 인한 사망이 처음 발생할 때까지 최대 3년간 추적 관찰
|
주기 1의 시작부터 진행, 이차성 악성 종양 또는 모든 원인으로 인한 사망이 처음 발생할 때까지 최대 3년간 추적 관찰
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- EPG-HU1418-201
- Health Canada (기타 식별자: 302929)
- 169169 (기타 식별자: United States Food and Drug Administration (FDA or USFDA))
- 2025-524397-42-00 (기타 식별자: European Union Clinical Trials Regulation (EU CTR), European Medicines Agency (EMA))
- 1013435 (기타 식별자: Integrated Research Application System (IRAS), Medicines and Healthcare products Regulatory Agency (MHRA))
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
At the current time there is no plan to share data. We have not received a research proposal that would require utilization of IPD. In the event we receive a request to access IPD a full evaluation will be undertaken and the data will be shared as appropriate and in compliance with the applicable regulations.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .